Buse JB - Search Results

1

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.

Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J; Liraglutide Effect Action in Diabetes-6 Study Group. Buse JB, et al. Diabetes Care. 2010 Jun;33(6):1300-3. doi: 10.2337/dc09-2260. Epub 2010 Mar 23. Diabetes Care. 2010. PMID: 20332351 Free PMC article. Clinical Trial.

2

The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies.

Buse J, Hart K, Minasi L. Buse J, et al. Clin Ther. 1998 Mar-Apr;20(2):257-69. doi: 10.1016/s0149-2918(98)80089-1. Clin Ther. 1998. PMID: 9589817 Clinical Trial.

3

Combining insulin and oral agents.

Buse J. Buse J. Am J Med. 2000 Apr 17;108 Suppl 6a:23S-32S. doi: 10.1016/s0002-9343(00)00339-9. Am J Med. 2000. PMID: 10764847 Review.

4

Should postprandial glucose be routinely measured and treated to a particular target? No!

Buse JB. Buse JB. Diabetes Care. 2003 May;26(5):1615-8. doi: 10.2337/diacare.26.5.1615. Diabetes Care. 2003. PMID: 12716828 Review. No abstract available.

5

Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker.

Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Buse JB, et al. Diabetes Technol Ther. 2003;5(3):355-63. doi: 10.1089/152091503765691839. Diabetes Technol Ther. 2003. PMID: 12828817

6

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Buse JB, et al. Diabetes Care. 2004 Nov;27(11):2628-35. doi: 10.2337/diacare.27.11.2628. Diabetes Care. 2004. PMID: 15504997 Clinical Trial.

7

Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon.

Buse JB, Rosenstock J. Buse JB, et al. Endocrinol Metab Clin North Am. 2005 Mar;34(1):221-35. doi: 10.1016/j.ecl.2004.11.003. Endocrinol Metab Clin North Am. 2005. PMID: 15752929 Review.

8

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Buse JB, et al. Clin Ther. 2005 Aug;27(8):1181-95. doi: 10.1016/j.clinthera.2005.08.005. Clin Ther. 2005. PMID: 16199244 Clinical Trial.

9

1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes.

Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S. Dungan KM, et al. Among authors: buse jb. Diabetes Care. 2006 Jun;29(6):1214-9. doi: 10.2337/dc06-1910. Diabetes Care. 2006. PMID: 16731998

10

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.

Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Association; American Diabetes Association. Buse JB, et al. Diabetes Care. 2007 Jan;30(1):162-72. doi: 10.2337/dc07-9917. Diabetes Care. 2007. PMID: 17192355 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

464 results

Search Page